LOGIN  |  REGISTER
Viking Therapeutics
Viking Therapeutics

Brookdale Senior Living Reports November 2024 Occupancy

December 09, 2024 | Last Trade: US$5.07 0.04 -0.78

NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) reported today its consolidated occupancy for November 2024.

Occupancy Chart

November 2024 Observations:

  • November weighted average occupancy increased 110 basis points year-over-year to 79.5% in 2024.
  • Demonstrating an improvement to recent years, November weighted average occupancy increased 10 basis points sequentially from October.
  • Month end occupancy exceeded 80% for the fourth consecutive month.
  • Fourth quarter-to-date move-ins and move-outs improved to the prior year comparable period supporting a 100 basis point weighted average occupancy increase over 2023 fourth quarter-to-date.

About Brookdale Senior Living

Brookdale Senior Living Inc. is the nation's premier operator of senior living communities. The Company is committed to its mission of enriching the lives of the people it serves with compassion, respect, excellence, and integrity. The Company, through its affiliates, operates independent living, assisted living, memory care, and continuing care retirement communities. Through its comprehensive network, Brookdale helps to provide seniors with care, connection, and services in an environment that feels like home. The Company's expertise in healthcare, hospitality, and real estate provides residents with opportunities to improve wellness, pursue passions, make new friends, and stay connected with loved ones. Brookdale, through its affiliates, operates and manages 648 communities in 41 states as of September 30, 2024, with the ability to serve approximately 58,000 residents. Brookdale's stock trades on the New York Stock Exchange under the ticker symbol BKD. For more information, visit brookdale.com or connect with Brookdale on Facebook or YouTube.

 

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB